Beam Therapeutics
NasdaqGS:BEAM Community- 1 Narratives written by author
- 0 Comments on narratives written by author
- 23 Fair Values set on narratives written by author
AN
Consensus Narrative from 15 Analysts
Advancing BEAM-101 And BEAM-302 Will Transform Treatment Of Hematology And Liver Genetic Diseases
Key Takeaways Promising programs in genetic diseases and innovative technology could significantly boost market share and revenue potential. Strategic advancements in gene editing could expand patient access and drive revenue growth through broader treatment availability.
View narrativeUS$49.40
FV
52.8% undervalued intrinsic discount2.41%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
1 day ago author updated this narrative